NAX Strengthens Leadership Team With Appointment of Patrick Nicolet - Former Capgemini Group CTO
9.9.2021 15:00:00 EEST | Business Wire | Press release
New Asset eXchange (NAX), a company that creates new markets and ecosystems around corporate assets, has today announced the appointment of Patrick Nicolet as Chair of its technology platform, Bridge.
Patrick Nicolet - formerly Group CTO and Executive Board Member at Capgemini - will lead NAX’s technology platform as it works on the development and deployment of enterprise-grade solutions to power digital asset economies. The platform’s current focus areas include coin & tokenization solutions, payment & disbursement processing, aggregated blockchain solutions and deployment services.
The arrival of Patrick Nicolet coincides with the appointment of Dr. Heiner Leisten as Chair of the Genesis Project, NAX’s development platform, and Joe Euteneuer as Chair of LiQid, NAX’s securitization platform. Both already sit on the NAX Board alongside high-profile business figures such as Frank Strauß, former Global CEO of Private and Commercial Banking at Deutsche Bank.
Jeff Schumacher, CEO and Founder, NAX said: “Patrick is a world-class technologist and business leader and brings vast experience to the team. His arrival further strengthens the NAX ecosystem; a development platform that mines corporate assets to create asset-backed ventures and markets, a technology platform that provides technology tools and solutions to power digital assets, and a securitization platform to make corporate assets tradeable. With Heiner, Patrick, and Joe at the helm of each, alongside our broader leadership team, we’re building an infrastructure that can fully realize the trillions of dollars of dormant value residing in corporate assets.”
NAX formally launched in January 2021 after two and a half years in stealth development. It focuses on building new markets and ecosystems around corporate assets. Led by serial entrepreneur Jeff Schumacher, NAX comprises three distinct but complementary platforms that provide a new lifecycle to repurpose corporate assets:
-
Creating asset backed ventures and markets
NAX’s development platform Genesis Project mines dormant corporate assets to create asset-backed ventures and markets.
-
Leveraging assets for DeFi
NAX’s technology platform Bridge deploys enterprise-grade technology solutions to power digital asset economies.
-
Making alternative assets tradeable
NAX’s trading platform LiQid securitizes corporate assets to make them tradeable.
Schumacher added: “The vast majority of assets globally are not listed. At NAX, we’re building an infrastructure to change that. From seed to securitization, we unlock value from underutilized corporate assets and, in doing so, are building next generation markets.”
About NAX
NAX enables a corporate partner to realize the full potential of its proprietary assets through the development of new asset-backed ventures and securities.
From seed to securitization, NAX co-leads the commercialization of these initiatives alongside its partners. It has three distinct but complementary platforms to repurpose corporate assets: a development platform, a technology platform and a securitization platform.
NAX maintains its headquarters in Manhattan Beach, CA and has offices in Palo Alto, New York, London, Paris, Zurich and Frankfurt.
For more information, visit http://www.naxgrp.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005501/en/
Contact information
Media contacts
Vested
Danny Calogero
nax@fullyvested.com
+447891 563 294
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom